Skip to Main Content

Paper Details

Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates.
Clin Cancer Res
3
2023
AML, FGFR, HGF, LY2874455, MET, Patients, Relapsed or Refractory Acute Myeloid Leukemia, acute myeloid leukemia, hepatocyte growth factor, leukemic blood, merestinib, myeloblast, patients
Author NameAffiliation
Daniel J DeAngeloDana-Farber Cancer Institute
Marlise R LuskinDana-Farber Cancer Institute
Eric P WinerDana-Farber Cancer Institute
Donna NeubergDana-Farber Cancer Institute
Alex LookDana-Farber Cancer Institute
Richard M StoneDana-Farber Cancer Institute
  • 1 - 6

Datasets

Release 1.2